TY - JOUR
T1 - A randomized, controlled trial of the toxin-blocking effects of B subunit in family members of patients with cholera
AU - Glass, Roger I.
AU - Holmgren, Jan
AU - Khan, M. R.
AU - Belayet Hossain, K. M.
AU - Imdadul Huq, M.
AU - Greenough, W. B.
N1 - Funding Information:
This research was supported by funds from the International Centre for Diarrhoeal Disease Research, Bangladesh; the Swedish Agency for Research Cooperation with Developing Countries; and the Swedish Medical Research Council.
PY - 1984
Y1 - 1984
N2 - A randomized, controlled field trial was performed to test the ability of B subunit, the nontoxic, binding portion of cholera toxin, to block the toxin receptors (G(M1) ganglioside) in the small intestine and thereby prevent diarrhea in individuals infected with Vibrio cholerae O1. Of 1,922 family contacts of 370 index patients selected randomly to receive orally on two successive days either B subunit (low dose, 1.0 mg; high dose, 5.0 mg) or placebo, 190 were asymptomatically infected on day 1 or day 2 of the study and within 24 h ots receiving B subunit. During the first 24-hr period of follow-up, the relative risk of disease among contact receiving B subunit versus placebo was 0.18 for the low dose (P = .08) and 0.50 for the high dose (P = .22). Subsequently the relative risk increased toward 1.0 and was at no single point significantly reduced, although in five of the six follow-up periods the risk of disease was less in the B subunit group.
AB - A randomized, controlled field trial was performed to test the ability of B subunit, the nontoxic, binding portion of cholera toxin, to block the toxin receptors (G(M1) ganglioside) in the small intestine and thereby prevent diarrhea in individuals infected with Vibrio cholerae O1. Of 1,922 family contacts of 370 index patients selected randomly to receive orally on two successive days either B subunit (low dose, 1.0 mg; high dose, 5.0 mg) or placebo, 190 were asymptomatically infected on day 1 or day 2 of the study and within 24 h ots receiving B subunit. During the first 24-hr period of follow-up, the relative risk of disease among contact receiving B subunit versus placebo was 0.18 for the low dose (P = .08) and 0.50 for the high dose (P = .22). Subsequently the relative risk increased toward 1.0 and was at no single point significantly reduced, although in five of the six follow-up periods the risk of disease was less in the B subunit group.
UR - http://www.scopus.com/inward/record.url?scp=0021364921&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021364921&partnerID=8YFLogxK
U2 - 10.1093/infdis/149.4.495
DO - 10.1093/infdis/149.4.495
M3 - Article
C2 - 6373961
AN - SCOPUS:0021364921
VL - 149
SP - 495
EP - 500
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 4
ER -